Bacteriophages, or “phages”, are viruses that can infect bacteria. With the number of bacteria that can evade antibiotics growing worryingly large, interest in using phages as therapies against drug-resistant infections has been rising. As we reported in 2023, phages have been used in Georgia for over a century, but they’re not approved for use in most other countries. Now, more than a year later, we’re asking: what would it take to bring a phage-therapy revolution to the rest of the world?

In this episode, The Economist’s Gilead Amit travels to the University of Leicester’s Centre for Bacteriophage Research in Britain to meet co-directors Martha Clokie and Andy Millard. We also revisit Gilead’s 2023 trip to the Eliava Institute in Georgia, where he met Mzia Kutateladze and her team, as well as Barry Rud, a patient at the institute. Are phages finally about to get the attention they deserve?

Transcripts of our podcasts are available via economist.com/podcasts.

Listen to what matters most, from global politics and business to science and technology—subscribe to Economist Podcasts+.

For more information about how to access Economist Podcasts+, please visit our FAQs page or watch our video explaining how to link your account.